Trientine HCl Cost in India: What You Need to Know
Trientine HCl, also known as trientine dihydrochloride, is a copper chelating agent used to treat Wilson's disease, a genetic disorder that causes excessive copper accumulation in the body. With the increasing demand for effective treatments, patients are looking for affordable options. In India, the cost of Trientine HCl can vary significantly depending on several factors.
Generic vs. Brand Name
In India, generic versions of Trientine HCl are widely available, which can offer significant cost savings compared to the brand name drug, Trientine HCl (Tricyte) by Takeda Pharmaceuticals. Generic versions are often manufactured by domestic companies, such as Cipla, Sun Pharma, and Zydus Cadila, among others.
Average Cost
According to various online pharmacy websites and medical stores in India, the average cost of Trientine HCl tablets (250 mg) is between ₹500 to ₹1,500 (approximately $6-$20 USD) per pack of 30 tablets, depending on the generic manufacturer. This can translate to a daily cost of ₹16 to ₹50 (approximately $0.20-$0.60 USD) per tablet.
Pharmacy Prices
Here are some approximate prices for Trientine HCl at various pharmacies in India:
- MedPlus Mart: ₹550 to ₹1,100 (approximately $7-$14 USD) per pack of 30 tablets
- 1mg: ₹540 to ₹1,260 (approximately $6.80-$15.50 USD) per pack of 30 tablets
- Netmeds: ₹540 to ₹1,020 (approximately $6.80-$12.60 USD) per pack of 30 tablets
Factors Affecting Cost
Several factors can influence the cost of Trientine HCl in India, including:
1. Manufacturer: Prices can vary depending on the generic manufacturer, with some offering lower prices than others.
2. Quantity: Buying in bulk or larger quantities can lead to lower prices per tablet.
3. Region: Prices may differ depending on the region or city in India.
4. Distribution channel: Online pharmacies, medical stores, or government hospitals may offer different prices for the same product.
Regulatory Framework
In India, Trientine HCl is approved by the Central Drug Standard Control Organization (CDSCO) and is available on the Indian market under the generic name. However, the patent for the brand-name version (Tricyte) is still valid in India, and the generic versions are available through various manufacturers.
According to DrugPatentWatch.com [1], the patent for Tricyte (Trientine HCl) is set to expire in 2028.
Conclusion
Trientine HCl is an essential medication for patients with Wilson's disease, and access to affordable treatment is crucial. In India, generic versions of Trientine HCl are widely available, offering a more cost-effective option compared to the brand-name drug. By choosing the right generic manufacturer, buying in bulk, and considering online pharmacies, patients can significantly reduce their medication costs.
Sources:
[1] DrugPatentWatch.com: Trientine Di Hydrochloride Patent Information (Takeda Pharmaceuticals)